Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.

Internal medicine journal - 1 Jul 2012

Muller K, Rodgers A, Wundke R, Waddell V, Altus R, Gordon D L, Wigg A

Abstract excerpt

BACKGROUND: Hepatitis C treatment is successful in 40-80% of patients in drug sponsored registration trials. However, few studies have examined treatment outcomes in non-trial, routine clinical practice settings. AIM: The aim of this study was to investigate the treatment outcomes and predictors of a sustained virological response in a routine clinical setting. METHODS: Data were collected retrospectively on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Ribavirin

Source

Identifiers

PMID: 22472126
DOI: 10.1111/j.1445-5994.2012.02798.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.PMID 22472126Read ↗

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.Semantic proximity Read ↗

Outcome of hepatitis C patients in a community with predominant genotype 3 with standard-of-care treatment before and after advent of direct-acting antivirals: A retrospective-cum-prospective study.Semantic proximity Read ↗

A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.Semantic proximity Read ↗

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).Semantic proximity Read ↗

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice.Semantic proximity Read ↗

Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice.Semantic proximity Read ↗

Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.Semantic proximity Read ↗

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.Semantic proximity Read ↗

Antiviral treatment of chronic hepatitis C in clinical routine.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?Semantic proximity Read ↗

Hepatitis C treatment at three Norwegian hospitals 2000-2011.Semantic proximity Read ↗

Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.